Skip to main content

Exploitation of Glycosylation Signatures for Precision Medicine

Objective

GlySign is a research training network for the translation of glycomic clinical biomarkers for Precision Medicine (PM). Complex, distinctive changes occur in the glycomics profiles or - Glycan Signatures - of human glycoproteins during progression of many chronic diseases including cancer and inflammatory conditions. The three beneficiaries of the GlySign Consortium have been instrumental in contributing to knowledge in this field through development of glycomics technology and discovery of clinically important novel glycan biomarkers in a variety of diseases.
Glycan signatures have great potential for adding useful diagnostic and prognostic information in PM. However, advancement of this field is slow because (a) glycans have immense structural complexity resulting in major technical challenges for their analysis and (b) there is a lack of experts with required glycoanalytical skills. GlySign will address this gap by training six young scientists within an innovative training-by-research programme with high industrial-academic mobility to eventually push forward the translation of novel glycomics-based diagnostic tools into clinical practice. This will be achieved by further developing a range of selective and sensitive glycomics technologies for the analysis of samples from patients and healthy controls in close collaboration between industry/academia as well as clinical chemists and clinicians who will be the end users of GlySign’s final products. To this end, we will focus the training on clinical glycomics applied to four model diseases implicating changes in the glycosylation of circulating proteins specific to disease progression or subtype, i.e. diabetes, prostate cancer, fetal and neonatal alloimmune thrombocytopenia and rheumatoid arthritis. Due to its strong industrial and translational focus, GlySign will, moreover, fill a current gap in the market by establishing new in vitro diagnostic platforms for clinical exploitation of glycomic biomarkers for PM.

Call for proposal

H2020-MSCA-ITN-2016
See other projects for this call

Coordinator

ACADEMISCH ZIEKENHUIS LEIDEN
Address
Albinusdreef 2
2333 ZA Leiden
Netherlands
Activity type
Higher or Secondary Education Establishments
EU contribution
€ 510 748,56

Participants (2)

LUDGER LIMITED
United Kingdom
EU contribution
€ 546 575,76
Address
Culham Science Centre - Building E1
OX14 3EB Abingdon
Activity type
Private for-profit entities (excluding Higher or Secondary Education Establishments)
GENOS DOO ZA VJESTACENJE I ANALIZU
Croatia
EU contribution
€ 495 522
Address
Vatrogasna 112
31000 Osijek
Activity type
Private for-profit entities (excluding Higher or Secondary Education Establishments)

Partners (4)

MAX-PLANCK-GESELLSCHAFT ZUR FORDERUNG DER WISSENSCHAFTEN EV
Germany
Address
Hofgartenstrasse 8
80539 Munchen
Activity type
Research Organisations
PROZOMIX LIMITED
United Kingdom
Address
Station Court 3
NE49 9HN Haltwhistle
Activity type
Private for-profit entities (excluding Higher or Secondary Education Establishments)
Stichting Sanquin Bloedvoorziening
Netherlands
Address
Plesmanlaan 125
1006 AN Amsterdam
Activity type
Research Organisations
ACADEMISCH MEDISCH CENTRUM BIJ DE UNIVERSITEIT VAN AMSTERDAM
Netherlands
Address
Meibergdreef 15
1105AZ Amsterdam
Activity type
Higher or Secondary Education Establishments